Vol. 28 Suppl. 2 2000
Pharmacokinetics and safety of T-593（Osutidine）, a new anti-ulcer agent, in healthy volunteers at Phase I study
M. Nakashima, et al.
Jpn Pharmacol Ther 2000 28(S2) 323
Pharmacokinetic analysis of T-593（Osutidine）, a novel anti-ulcer agent, in a Phase I study using a three-step discontinuous
absorption model
M. Noguchi, et al.
Jpn Pharmacol Ther 2000 28(S2) 337
Effect of a novel antiulcer-drug T-593（Osutidine）on nocturnal gastric juice secretion
Y. Matsuo, et al.
Jpn Pharmacol Ther 2000 28(S2) 349
Clinical utility of T-593（Osutidine）, a novel anti-ulcer agent, for treatment of gastric ulcer
―A pilot study―
T. Miwa, et al.
Jpn Pharmacol Ther 2000 28(S2) 361
Clinical utility of T-593（Osutidine）, a novel anti-ulcer agent, for the treatment of gastric ulcer and duodenal
ulcer
―Dose determination study―
T. Miwa, et al.
Jpn Pharmacol Ther 2000 28(S2) 371
Effect of T-593（Osutidine）, a new anti-ulcer agent, on intragastric pH（First Report）
―A dose comparative study by 24-hour intragastric pH monitoring―
T. Shimatani, et al.
Jpn Pharmacol Ther 2000 28(S2) 393
Effect of T-593（Osutidine）, a new anti-ulcer agent,on intragastric pH（Second Report）
―A comparative study between a dosage of 400 mg once a day and 200 mg twice a day by 24-hour intragastric pH monitoring―
T. Shimatani
Jpn Pharmacol Ther 2000 28(S2) 401
Clinical utility of T-593（Osutidine）for the treatment of gastric ulcer
―Comparison with famotidine in a multi-center double-blind study―
T. Miwa, et al.
Jpn Pharmacol Ther 2000 28(S2) 409
Clinical utility of T-593（Osutidine） for the treatment
of duodenal ulcer
―Comparison with famotidine in a multi-center double-blind study―
T. Miwa, et al.
Jpn Pharmacol Ther 2000 28(S2) 431
Clinical efficacy of T-593（Osutidine）on gastric ulcer
―Electronic endoscopic evaluation of quality of ulcer healing―
H. Asakura, et al.
Jpn Pharmacol Ther 2000 28(S2) 451
Clinical efficacy of T-593（Osutidine）on gastric ulcer resistant to H2-receptor antagonist and/or proton pump inhibitor
T. Miwa, et al.
Jpn Pharmacol Ther 2000 28(S2) 471
Therapeutic effects of T-593（Osutidine）on peptic ulcer
induced by non-steroidal anti-inflammatory drugs（NSAID）during NSAID administration
M. Nobunaga, et al.
Jpn Pharmacol Ther 2000 28(S2) 491
Clinical effects of T-593（Osutidine）on endocrine function
and healing in patients with peptic ulcer
Y. Miyachi, et al.
Jpn Pharmacol Ther 2000 28(S2) 507
Clinical efficacy of T─593（Osutidine）on gastrin and secretin and the healing of gastric and duodenal ulcer
H. Fukutomi, et al.
Jpn Pharmacol Ther 2000 28(S2) 521
Clinical efficacy of T-593（Osutidine）on gastrin and pepsinogen and the healing of gastric and duodenal ulcers
T. Takahashi, et al.
Jpn Pharmacol Ther 2000 28(S2) 535
Clinical efficacy of T-593（Osutidine）in one nocturnal dose daily on the healing of gastric and duodenal ulcers
T. Miwa, et al.
Jpn Pharmacol Ther 2000 28(S2) 549
Clinical efficacy of an 800 mg daily dose of T-593（Osutidine）on the healing of gastric and duodenal ulcers
T. Miwa, et al.
Jpn Pharmacol Ther 2000 28(S2) 561
Pharmacokinetics of T-593（Osutidine）, a new anti-ulcer agent, following single oral dosing in elderly and young volunteers
S. Kobayashi, et al.
Jpn Pharmacol Ther 2000 28(S2) 575
Pharmacokinetics of T-593（Osutidine）in patients with renal insufficiency or failure
K. Kobayashi, et al.
Jpn Pharmacol Ther 2000 28(S2) 585
Clinical evaluation of T-593（Osutidine）on reflux esophagitis
T. Sekiguchi, et al.
Jpn Pharmacol Ther 2000 28(S2) 597
Therapeutic effects of T-593（Osutidine）on post-operative recurrent ulcer including stomal ulcer
Y. Watanabe, et al.
Jpn Pharmacol Ther 2000 28(S2) 609
